RPH-075

DRUG2 trials

Sponsors

R-Pharm

Conditions

Head and Neck Squamous Cell CarcinomaSkin MelanomaSquamous Non-small-cell Lung Cancer

Phase 1

Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms

Active, not recruitingNCT06307093

R-PharmHead and Neck Squamous Cell Carcinoma, Skin Melanoma, Squamous Non-small-cell Lung Cancer

Start: 2023-03-01End: 2025-07-31Updated: 2024-03-12

Phase 3

Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma

Active, not recruitingNCT06320353

R-PharmSkin Melanoma

Start: 2023-09-27End: 2026-01-31Updated: 2024-03-20

Related Papers

Results of phase III clinical trial of novel biosimilar of pembrolizumab (RPH-075).

Journal of Clinical Oncology2025-05-28